Description

[5α,7α(S)]-17-(Cyclopropylmethyl)-α-(1,1-Dimethylethyl)-4,5-Epoxy-3,6-Dimethoxy-α-Methyl-6,14-Ethenomorphinan-7-Methanol is a complex, high-purity synthetic opioid derivative of significant interest in advanced pharmaceutical research and development. This compound serves as a critical intermediate or reference standard for the synthesis and analytical study of novel therapeutic agents targeting the central nervous system. It is primarily required by pharmaceutical R&D laboratories, contract research organizations (CROs), and academic institutions engaged in neuropharmacology, medicinal chemistry, and analytical method development.

Application

• Pharmaceutical Intermediate: Key building block in the synthetic pathway for novel opioid-based analgesics and other CNS-active pharmaceutical compounds.
• Reference Standard: Used as a certified reference material (CRM) for the qualitative and quantitative analysis (e.g., HPLC, GC-MS) of related substances in drug development and quality control.
• Medicinal Chemistry Research: A vital tool for structure-activity relationship (SAR) studies to understand and modify the pharmacological profile of morphinan derivatives.
• Metabolite Studies: Employed in the identification and characterization of potential metabolites during preclinical and clinical drug development stages.
• Impurity Profiling: Serves as a known impurity or degradation product standard to ensure the purity and safety profile of final active pharmaceutical ingredients (APIs).
• Academic Research: Used in university and institutional labs for fundamental research on opioid receptor binding and signal transduction mechanisms.

Basic Information

Product Name	[5α,7α(S)]-17-(Cyclopropylmethyl)-α-(1,1-Dimethylethyl)-4,5-Epoxy-3,6-Dimethoxy-α-Methyl-6,14-Ethenomorphinan-7-Methanol
CAS No.	155203-04-6
Molecular Formula	C30H41NO4
Molecular Weight	479.65 g/mol
Synonyms	Buprenorphine Impurity F; Buprenorphine Related Compound F; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-3,6-dimethoxy-α-methyl-, (5α,7α(S))-; α-Tert-butylbuprenorphine; (2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-4,5-epoxy-3,6-dimethoxy-6,14-ethano-6,7,8,14-tetrahydrothebain-7-yl]-3,3-dimethylbutan-2-ol
EINECS	Contact for details

Quality Control

Every batch of our [5α,7α(S)]-17-(Cyclopropylmethyl)-α-(1,1-Dimethylethyl)-4,5-Epoxy-3,6-Dimethoxy-α-Methyl-6,14-Ethenomorphinan-7-Methanol is manufactured and analyzed under strict quality management systems. We provide comprehensive analytical data to support its use in regulated environments. A detailed Certificate of Analysis (COA) is supplied with each shipment, confirming identity, purity, and other critical parameters as per client specifications or standard pharmacopeial guidelines.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed in a dry environment to prevent moisture absorption. For long-term storage, consider desiccants or inert atmosphere packaging.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.